Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-azacitidine plus thalidomide for myelodysplastic syndromes
ACTRN12607000283471Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jul 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and thalidomide in myelodysplastic syndrome (MDS), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Hematologic and non-hematologic toxicity. Started Jul 2008; status: completed.
02
Drugs
azacitidinethalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12607000283471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000283471.